WuXi PharmaTech Announces Resignation of Board Member Cuong Viet Do

SHANGHAI, Sept. 30, 2011 /PRNewswire-Asia/ --WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced that Cuong Viet Do is stepping down from WuXi's board of directors effective immediately.  Mr. Do has been appointed Chief Strategy Officer of Merck and Company, which is a large WuXi customer.

"I would like to thank Cuong for serving on WuXi's board for the past four years and for his wisdom and guidance," said Dr. Ge Li, chairman and CEO.  "We will miss Cuong and wish him the best in his new position at Merck."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.

For more information, please contact:

WuXi PharmaTech (Cayman) Inc.

Ronald Aldridge (for investors)

Director of Investor Relations

Tel: +1-201-585-2048

Email: [email protected]

Stephanie Liu (for the media)

WuXi PharmaTech (Cayman) Inc.

Tel: +86-21-5046-4362

Email: [email protected]

SOURCE WuXi PharmaTech (Cayman) Inc